共 50 条
- [21] Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectivesCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 139 : 53 - 66Vernieri, ClaudioMilano, MonicaBrambilla, MartaMennitto, AlessiaMaggi, ClaudiaCona, Maria SilviaPrisciandaro, MicheleFabbroni, ChiaraCelio, LuigiMariani, GabriellaBianchi, Giulia ValeriaCapri, Giuseppede Braud, Filippo
- [22] Genomic Alterations of Tumors in HER2-Low Breast CancersINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (02)Tsai, Yi-FangHuang, Chi-ChengHsu, Chih-YiFeng, Chin-JungLin, Yen-ShuChao, Ta-ChungLai, Jiun-, ILien, Pei-JuLiu, Chun-YuChiu, Jen-HweyTseng, Ling-Ming
- [23] Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+breast cancer (BC)CANCER RESEARCH, 2021, 81 (04)Sethunath, VidyalakshmiFu, XiaoyongLuna, Pamela L.Nanda, SarmisthaShea, MartinVeeraraghavan, JamunaraniDe Angelis, CarmineHu, HuizhongShaw, ChadRimawi, MothaffarOsborne, C. KentSchiff, Rachel
- [24] De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancerPHARMACOGENOMICS, 2015, 16 (12) : 1411 - 1426Madrid-Paredes, AdelaCanadas-Garre, MarisaSanchez-Pozo, AntonioAngel Calleja-Hernandez, Miguel
- [25] Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial DistributionCANCERS, 2023, 15 (05)Giugliano, FedericaCarnevale Schianca, AmbraCorti, ChiaraIvanova, MariiaBianco, NadiaDellapasqua, SilviaCriscitiello, CarmenFusco, NicolaCurigliano, GiuseppeMunzone, Elisabetta
- [26] Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patternsJOURNAL OF CLINICAL PATHOLOGY, 2024,Lv, HongBai, Qian-MingLi, MingCai, Meng-YuanZhou, Shu-LingLiu, YinWang, Zhong-HuaShui, Ruo-HongLu, Hong-FenXu, Xiao-LiYu, Bao-HuaTu, Xiao-YuBi, RuiCheng, Yu-FanZhou, Xiao-YanShao, Zhi-MinYang, Wen-Tao
- [27] IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+breast cancerPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (31)Ong, Li-TengLee, Wee ChyanMa, ShijunOguz, GokceNiu, ZhitongBao, YiYusuf, MubarakaLee, Puay LengGoh, Jian YuanWang, PanpanYong, Kylie Su MeiChen, QingfengWang, WenyuRamasamy, AdaikalavanHoon, Dave S. B.Ditzel, Henrik J.Tan, Ern YuLee, Soo ChinYu, Qiang
- [28] Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapiesCANCER, 2016, 122 (17) : 2654 - 2662Ross, Jeffrey S.Gay, Laurie M.Wang, KaiAli, Siraj M.Chumsri, SaranyaElvin, Julia A.Bose, RonVergilio, Jo-AnneSuh, JamesYelensky, RomanLipson, DoronChmielecki, JuliannWaintraub, StanleyLeyland-Jones, BrianMiller, Vincent A.Stephens, Philip J.
- [29] Fatty acid uptake as a potentially new resistance mechanism to anti-HER2 treatments in HER2-positive breast cancerCANCER RESEARCH, 2020, 80 (04)Vernieri, ClaudioCastagnoli, LorenzoLigorio, FrancescaBelfiore, AntoninoFasano, ElenaCorsetto, Paola A.Faraci, SimonaBrambilla, MartaCorti, FrancescaTriulzi, TizianaGenerali, DanieleVingiani, AndreaRizzo, Angela M.Bianchi, Giulia V.Capri, GiuseppeTagliabue, EldaDe Braud, FilippoPruneri, GiancarloPupa, Serenella M.
- [30] Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+breast cancer patients with prior anti-HER2 therapyCANCER RESEARCH, 2019, 79 (04)Im, S-ABang, Y-JOh, D-YGiaccone, G.Bauer, T.Nordstrom, J.Li, H.Moore, P.Hong, S.Baughman, J.Rock, E.Burris, H.